Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can eating only 6-8 hours a day help people with type 1 diabetes lose weight and control blood sugar?

NCT ID NCT06134986

Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared time-restricted eating (eating only during a 6-8 hour window each day) to daily calorie restriction for weight loss and blood sugar control in 32 adults with type 1 diabetes and obesity. Participants followed their assigned diet while continuing insulin and glucose monitoring. The goal was to see if the simpler fasting approach could help with weight management and improve blood sugar levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

32 people

The number who actually took part.

Started

Nov 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previously diagnosed with T1DM and currently using insulin * HbA1c: 6.5-9.5% (regardless of medication use) * Age between 18 to 75 years old * BMI between 25 and 50 kg/m2 * Independently living (i.e., subjects who do not live in a nursing home or institution) * On either multiple daily doses of insulin injections (MDII) or using an insulin pump (with or without closed loop feature) * Active prescription for daily use of a continous glucose monitor (CGM) or willing to be provided with a CGM during the study (at no cost) * Active prescription for glucagon Exclusion Criteria: * History of severe hypoglycemia defined as requiring help from others, needed to use emergency glucagon administration in the past 6 months. * Medical history of heart failure, unstable coronary artery disease, chronic obstructive pulmonary disease, requiring oxygen, cirrhosis, active cancer, history of stroke, cognitive impairment, end stage renal disease (eGFR ≤30 ml/min/m2) * Previously diagnosed with T2DM * Have a history of eating disorders (anorexia, bulimia, or binge eating disorder) * Are not weight stable for 3 months prior to the beginning of study (weight gain or loss \> 4%) * Are not able to keep a food diary for 7 consecutive days during screening * Are taking certain drugs that have significant weight loss outcomes (weight loss medications, specifically GLP1 agonist, GLP-1/GIP agonists) * Are eating less than a 10-hour window at baseline * Are perimenopausal (menses does not appear every 27-32d) * Are pregnant, or trying to become pregnant * Are night shift workers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Type 1 diabetes

Contacts and locations

Locations

  • University of Illinois Chicago

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.